Posted by Michael Wonder on 10 Sep 2021
ICER publishes evidence report on treatments for myasthenia gravis
10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than 95% lower than eculizumab’s current US list price to reach common thresholds for cost effectiveness.
The Institute for Clinical and Economic Review today released its revised Evidence Report assessing the comparative clinical effectiveness and value of eculizumab (Soliris; Alexion Pharmaceuticals) and efgartigimod (argenx, Halozyme Therapeutics, and Zai Lab) for the treatment of generalized myasthenia gravis.
